Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.

about

Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.

Item

http://www.wikidata.org/entity/Q40129891

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Reduced BUCY 2 and G-CSF-prime ...... mortality in allogeneic HSCT.

@en

type

Item

label

Reduced BUCY 2 and G-CSF-prime ...... mortality in allogeneic HSCT.

@en

prefLabel

Reduced BUCY 2 and G-CSF-prime ...... mortality in allogeneic HSCT.

@en

P1476

Reduced BUCY 2 and G-CSF-prime ...... d mortality in allogeneic HSCT

@en

P2093

Eucario Leon Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No!

Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.

P304

1525-1531

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3056-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mónica M Rivera Franco

Sandra I Perez Alvarez

P577

2017-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28691152

http://www.w3.org/2001/XMLSchema#string

Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.

about

Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698